UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K/A
Amendment
No. 1
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
June 17, 2009
Date of Report (Date of earliest event reported)
HLTH CORPORATION
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
0-24975
|
|
94-3236644 |
|
|
|
|
|
(State or other jurisdiction of
incorporation)
|
|
(Commission File Number)
|
|
(I.R.S. Employer
Identification No.) |
669 River Drive, Center 2
Elmwood Park, New Jersey 07407-1361
(Address of principal executive offices, including zip code)
(201) 703-3400
(Registrants telephone number, including area code)
(Former name or address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
|
|
|
þ
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
|
o
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
|
o
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR 240.14d-2(b)) |
|
|
|
o
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act
(17 CFR 240.13e-4(c)) |
This Amendment No. 1 is being filed to add Exhibit 2.1 to this Current Report on Form 8-K and to
reflect that addition in Items 1.01 and 9.01. In the original Current Report filing, we had indicated that
Exhibit 2.1 would be added by amendment.
All statements contained in this Current Report, other than statements of historical fact, are
forward-looking statements, including those regarding: expected benefits from and effects of the
merger transaction between HLTH Corporation and WebMD Health Corp. (the Merger) and the potential
sale transaction with respect to Porex (the Potential Porex Sale). These statements speak only as
of the date of this Current Report, are based on HLTHs and WebMDs current plans and expectations,
and involve risks and uncertainties that could cause actual future events or results to be
different than those described in or implied by such forward-looking statements. These risks and
uncertainties include those relating to: market acceptance of HLTHs and WebMDs products and
services; HLTHs and WebMDs relationships with customers and strategic partners; changes in the
markets for auction rate securities; and changes in economic, political or regulatory conditions or
other trends affecting the healthcare, Internet, information technology and plastics industries.
Further information about these matters can be found in HLTHs and WebMDs other Securities and
Exchange Commission filings. In addition, there can be no assurances regarding: whether HLTH and
WebMD will be able to complete the Merger or as to the timing of such transaction; or whether HLTH
will be able to complete the Potential Porex Sale or as to the timing or terms of such transaction.
Except as required by applicable law or regulation, we do not undertake any obligation to update
our forward-looking statements to reflect future events or circumstances.
Item 1.01. Entry into a Material Definitive Agreement
On June 17, 2009, HLTH Corporation and WebMD Health Corp. entered into an Agreement and Plan
of Merger (the Merger Agreement). The Merger Agreement provides that HLTH will merge into WebMD,
with WebMD continuing as the surviving company (the Merger). HLTH currently owns all 48.1
million outstanding shares of WebMD Class B Common Stock. The merger will eliminate both the
controlling class of WebMD stock held by HLTH and WebMDs existing dual-class stock structure. In
the merger, the WebMD Class B shares will be retired and each outstanding share of HLTH Common
Stock will be converted into 0.4444 shares of WebMD Common Stock. Shares of WebMD Class A Common
Stock will remain outstanding and will be unchanged in the merger. A copy of the press release
announcing the Merger is filed as Exhibit 99.1 to this Current Report and is incorporated herein by
reference.
The Merger Agreement contains customary representations, warranties and covenants that the
parties made to each other, including, among others, covenants by each of HLTH and WebMD to conduct
its business in the ordinary course between the signing of the Merger Agreement and completion of
the Merger, and to maintain and preserve its business organizations and relationships during such
period, except as contemplated by the Merger Agreement. A copy of the
Merger Agreement is
filed as Exhibit 2.1 to this Current Report in order to
provide investors with information regarding the terms of the Merger Agreement and is not intended
to be, and should not be relied upon as, disclosures regarding any facts and circumstances relating
to HLTH or WebMD. The representations and warranties contained in the Merger Agreement have been
negotiated with the principal purpose of establishing the circumstances in which either party may
have the right not to consummate the Merger, or a party may have the right to terminate the Merger
Agreement, if the representations and warranties of the other party prove to be untrue due to a
change in circumstance or otherwise, and allocates risk between the parties, rather than
establishing matters as facts. In addition, the representations and warranties contained in the
Merger Agreement may also be subject to a contractual standard of materiality different from those
generally applicable to investors.
Additional Information About the Proposed Merger of HLTH and WebMD and Where to Find It:
In connection with the proposed Merger, HLTH and WebMD expect to file, with the SEC, a proxy
statement/prospectus as part of a registration statement regarding the proposed transaction.
Investors and security holders are urged to read the proxy statement/prospectus because it will
contain important information about HLTH and WebMD and the proposed transaction. Investors and
security holders may obtain a free copy of the definitive proxy statement/prospectus and other
documents when filed by HLTH and WebMD with the SEC at www.sec.gov or www.hlth.com or www.wbmd.com.
Investors and security holders are urged to read the proxy statement/prospectus and other relevant
material when they become available before making any voting or investment decisions with respect
to the Merger.
2
Participants in the Merger
HLTH, WebMD, their directors and certain of their executive officers may be considered
participants in the solicitation of proxies in connection with the proposed transaction.
Information about the directors and executive officers of HLTH and WebMD and their respective
interests in the proposed transactions will be set forth or incorporated by reference in the proxy
statement/prospectus that HLTH and WebMD will file with the SEC in connection with the proposed
transaction. Information about the directors and executive officers of HLTH is available in Item
10 of HLTHs Annual Report on Form 10-K for the Year Ended December 31, 2008, included in an
Amendment to that Form 10-K filed with the SEC on April 30, 2009. Information about the directors
and executive officers of WebMD is available in Item 10 of WebMDs Annual Report on Form 10-K for
the Year Ended December 31, 2008, included in an Amendment to that Form 10-K filed with the SEC on
April 30, 2009. Investors may obtain additional information regarding the interests of such
participants by reading the proxy statement/prospectus when it becomes available.
|
|
|
Item 9.01. |
|
Financial Statements and Exhibits |
(d) Exhibits. The following exhibits are filed herewith:
|
|
|
Exhibit |
|
|
Number |
|
Description |
|
|
|
2.1*
|
|
Agreement and Plan of Merger, dated as of June 17, 2009, between
HLTH Corporation and WebMD Health Corp. |
|
|
|
99.1**
|
|
Press Release, dated June 18, 2009, regarding the Merger |
|
|
|
* |
|
The schedules to Exhibit 2.1
are omitted from this filing pursuant to Item 601(b)(2) of Regulation S-K. The
Registrant will furnish copies of any of the omitted schedules to
the Securities and Exchange Commission upon request. |
|
** |
|
Previously filed. |
3